Karis Bio
Karis Bio Inc. is a leading company in innovative cell therapy for cardiovascular diseases, focusing on developing regenerative medicine solutions using patented iPSC technology. The company aims to develop and commercialize cell-based therapies, including blood vessel growth and vasculogenesis, targeting diseases such as peripheral arterial disease and critical limb ischemia. With over 20 years of experience, Karis Bio is committed to advancing regenerative medicine and establishing a global presence in the biotech industry.
Industries
Nr. of Employees
small (1-50)
Karis Bio
Patents
Method of isolation of culture of vascular endothelial cells, medium for maintaining characteristics of vascular endothelial cells, and culture method including same
US-12447181-B2
View Details
Method of isolation of culture of vascular endothelial cells, medium for maintaining characteristics of vascular endothelial cells, and culture method including same
US-12447181-B2
View DetailsProducts
iPSC-derived endothelial cell therapy for peripheral arterial disease and related ischemic conditions
A therapeutic cell product composed of endothelial cells differentiated from human iPSCs intended to promote neovascularization in peripheral arterial disease, critical limb ischemia and other ischemic indications.
Directly reprogrammed cardiac-like tissue therapy
Therapeutic approach based on direct conversion of somatic cells into cardiac-like tissue containing major cardiac cell types and extracellular matrix for heart regeneration.
Combination therapy: iPSC-derived vascular cells with peptide-based nanomatrix
A hybrid therapeutic combining iPSC-derived endothelial cells with a peptide-based nanomatrix scaffold intended to enhance engraftment and vascularization in ischemic organs.
iPSC-derived endothelial cell therapy for peripheral arterial disease and related ischemic conditions
A therapeutic cell product composed of endothelial cells differentiated from human iPSCs intended to promote neovascularization in peripheral arterial disease, critical limb ischemia and other ischemic indications.
Directly reprogrammed cardiac-like tissue therapy
Therapeutic approach based on direct conversion of somatic cells into cardiac-like tissue containing major cardiac cell types and extracellular matrix for heart regeneration.
Combination therapy: iPSC-derived vascular cells with peptide-based nanomatrix
A hybrid therapeutic combining iPSC-derived endothelial cells with a peptide-based nanomatrix scaffold intended to enhance engraftment and vascularization in ischemic organs.
Services
On-site manufacturing and GMP operations for clinical-stage cell therapy products, including cleanroom production, QA/QC and environmental monitoring.
Provision of licensed access to induced pluripotent stem cell lines and related IP arrangements to support product development.
Collaborative research projects with academic and government partners, including development of cardiovascular-model-based prediction tools and platform R&D funded by public agencies.
On-site manufacturing and GMP operations for clinical-stage cell therapy products, including cleanroom production, QA/QC and environmental monitoring.
Provision of licensed access to induced pluripotent stem cell lines and related IP arrangements to support product development.
Collaborative research projects with academic and government partners, including development of cardiovascular-model-based prediction tools and platform R&D funded by public agencies.
Expertise Areas
- iPSC-derived cell therapy development
- Direct cellular reprogramming for cardiac repair
- Regenerative medicine for cardiovascular disease
- cGMP cell therapy manufacturing
Key Technologies
- Induced pluripotent stem cell generation
- Endothelial cell differentiation from iPSCs
- Direct reprogramming of fibroblasts to cardiac-like tissue
- Vascularized cardiac organoid generation
News & Updates
Karis Bio opened a new GMP manufacturing facility for cell therapy products in Gasan-dong, Seoul.
The company received the Good-Bio Award in the Cell Therapy for Cardiovascular Disease category for the third consecutive year.
Secured additional funding of $725,000 from Korea Venture Investment Corp. in 2023.
Karis Bio develops advanced cell therapies using iPSC technology to treat cardiovascular diseases, aiming to become a global leader in regenerative medicine.
Received for excellence in cell therapy for cardiovascular disease at the Korea Good Company Awards.
Published in Nature Biomedical Engineering, demonstrating therapeutic effects in mouse models.
Karis Bio opened a new GMP manufacturing facility for cell therapy products in Gasan-dong, Seoul.
The company received the Good-Bio Award in the Cell Therapy for Cardiovascular Disease category for the third consecutive year.
Secured additional funding of $725,000 from Korea Venture Investment Corp. in 2023.
Karis Bio develops advanced cell therapies using iPSC technology to treat cardiovascular diseases, aiming to become a global leader in regenerative medicine.
Received for excellence in cell therapy for cardiovascular disease at the Korea Good Company Awards.
Published in Nature Biomedical Engineering, demonstrating therapeutic effects in mouse models.